
Congresos
Materiales de congresos
Tenga acceso a resúmenes, pósteres y presentaciones de los siguientes congresos
Marzo 2023
American Society for Clinical Pharmacology & Therapeutics (ASCPT)
American Society for Clinical Pharmacology & Therapeutics (ASCPT)
March 2023 (Atlanta, Georgia, USA)
Marzo 2023
JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)
JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)
Marzo 2023 (París, Francia)
Marzo 2023
JSMO (Sociedad Japonesa de Oncología Médica)
JSMO (Sociedad Japonesa de Oncología Médica)
March 2023 (Fukuoka, Japan)
Febrero 2023
International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM )
International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM )
February 2023 (Miami Beach, Florida, USA)
Pósteres
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study
Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib in patients with B-cell malignancies intolerant to acalabrutinib
Resúmenes
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study
Rate of cardiac disorders in patients (pts) with B-cell malignancies who undergo treatment with zanubrutinib (zanu)
Zanubrutinib (zanu) in patients (pts) with B-cell malignancies intolerant to acalabrutinib (acala)
Febrero 2023
ASCO-GU (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Genitourinarios)
ASCO-GU (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Genitourinarios)
February 2023 (San Francisco, California, USA)
Febrero 2023
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem)
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem)
February 2023 (Orlando, Florida, USA)
Enero 2023
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
January 2023 (San Francisco, California, USA)
Presentaciones
RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Pósteres
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Resúmenes
RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Diciembre 2022
ASH (Sociedad Estadounidense de Hematología)
ASH (Sociedad Estadounidense de Hematología)
December 2022 (New Orleans, Louisiana, USA)
Presentaciones
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Zanubrutinib demonstrates superior progression-free surivival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study
Pósteres
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia: preliminary data
Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies
Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies
Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relaped/refractory MCL: an updated pooled analysis
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia
Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a nonrandomized, open-label, phase 1b/2 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Resúmenes
A phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM): preliminary data
A phase 1 with the novel B-cell lymphoma 2 (Bcl-1) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data
Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies
Development of hypertension and atrial fibrillation following diagnosis of B-cell malignancies - a retrospective analysis of US MarketScan insurance claims database
Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies
Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed/refractory MCL: an updated pooled analysis
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML)
Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study
Real-world evidence (RWE) studies supported hematologic oncology United States Food and Drug Administration (US FDA) approval: what do they look like?
Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): results from final analysis of ALPINE randomized phase 3 study
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Diciembre 2022
ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)
ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)
Diciembre 2022 (Ginebra, Suiza)
Pósteres
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced NSCLC
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer: RATIONALE-304 updated analysis
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer: RATIONALE-307 updated analysis
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced non-small cell lung cancer
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer : RATIONALE-304 updated analysis
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer : RATIONALE-307 updated analysis
Diciembre 2022
ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)
ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)
December 2022 (Singapore)
Presentaciones
Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Randomized, global, phase 3 study of tislelizumab plus chemotherapy vs chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: the RATIONALE-301 Chinese subpopulation analysis
Resúmenes
Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
RATIONALE-302: tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): impact on health-related quality of life (HRQoL) in Asian patients
RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 Chinese subpopulation analysis
Noviembre 2022
DKK (Congreso oncológico de Alemania)
DKK (Congreso oncológico de Alemania)
Noviembre 2022 (Berlín, Alemania)
Noviembre 2022
KALC (Asociación Coreana de Cáncer de Pulmón)
KALC (Asociación Coreana de Cáncer de Pulmón)
Noviembre 2022 (Seúl, Corea del Sur)
Presentaciones
Noviembre 2022
SITC (Sociedad de Inmunoterapia contra el Cáncer)
SITC (Sociedad de Inmunoterapia contra el Cáncer)
November 2022 (Boston, Massachusetts, USA)
Pósteres
DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial
Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study
Resúmenes
DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial
Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study
Noviembre 2022
SPH (Sociedad Portuguesa de Hematología)
SPH (Sociedad Portuguesa de Hematología)
Noviembre 2022 (Tróia, Portugal)
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
Long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
Noviembre 2022
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)
Noviembre 2022 (Viena, Austria)
Pósteres
Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Budget impact analysis of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals
Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States
Resúmenes
Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Budget impact of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia in the United States
Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals
Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States
Noviembre 2022
CSCO (Sociedad China de Oncología Clínica)
CSCO (Sociedad China de Oncología Clínica)
Noviembre 2022 (China)
Presentaciones
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study
Pósteres
RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer
RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for nonsquamous nsclc in patients aged 65-75 years
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (her2+) advanced/metastatic gastroesophageal adenocarcinoma
HERIZON-GEA-01: a phase 3 study of zanidatamabin combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Resúmenes
Time to response and depth of response in non-squamous non-small cell lung cancer patients treated with tislelizumab plus chemotherapy as first line therapy: an exploratory analysis of RATIONALE-304
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study
RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first line treatment for nonsquamous non-small cell lung cancer in patients aged 65-75 years
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
A matching-adjusted indirect comparison of tislelizumab versus camrelizumab as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
AdvanTIG-105: a phase 1 dose-verification study of ociperlimab in combination with tislelizumab in advanced solid tumors in Chinese patients
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Rationale-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen
Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in patients with previously treated advanced squamous non-small cell lung cancer: sub-analysis from phase 3 RATIONALE-303 randomized clinical study
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Zanubrutinib plus obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Noviembre 2022
COSA (Sociedad Australiana de Oncología Clínica)
COSA (Sociedad Australiana de Oncología Clínica)
Noviembre 2022 (Brisbane, Australia)
Pósteres
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103
Resúmenes
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer
Octubre 2022
IWWM (Taller internacional sobre la macroglobulinemia de Waldenström)
IWWM (Taller internacional sobre la macroglobulinemia de Waldenström)
Octubre 2022 (Madrid, España)
Presentaciones
ASPEN biomarker analysis: response to BTK inhibitor treatment in patients with Waldenström macroglobulinemia harboring CXCR4, TP53, and TERT mutations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Extended follow-up of a phase 2 trial of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia
Zanubrutinib in patients intolerant to ibrutinib/acalabrutinib
Zanubrutinib or the treatment of patients with Waldenström macroglobulinemia: 4 years of follow-up
Resúmenes
ASPEN biomarker analysis: response to Bruton Tyrosine Kinase Inhibitor (BTKi) treatment in patients with Waldenström macroglobulinemia (WM) harboring CXCR4, TP53, and TERT mutations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
Extended follow-up of a phase 2 trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia
Preliminary results for patients with Waldenström macroglobulinemia from the phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Octubre 2022
JSCO (Sociedad Japonesa de Oncología Clínica)
JSCO (Sociedad Japonesa de Oncología Clínica)
Octubre 2022 (Kobe, Japón)
Octubre 2022
Linfoma, leucemia y mieloma (LLM)
Linfoma, leucemia y mieloma (LLM)
October 2022 (New York, New York, USA)
Octubre 2022
JSH (Sociedad Japonesa de Hematología)
JSH (Sociedad Japonesa de Hematología)
Octubre 2022 (Fukuoka, Japón)
Octubre 2022
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)
Octubre 2022 (Viena, Austria)
Presentaciones
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Pósteres
Randomized, phase 3 study of second-line treatment vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQOL)
Octubre 2022
SEHH (Sociedad Española de Hematología y Hemoterapia)
SEHH (Sociedad Española de Hematología y Hemoterapia)
Octubre 2022 (Barcelona, España)
Presentaciones
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (Bcl-2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve CLL/SLL
Pósteres
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
Septiembre 2022
SOHO (Sociedad de Oncología Hematológica)
SOHO (Sociedad de Oncología Hematológica)
September 2022 (Houston, Texas, USA)
Pósteres
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs. ibrutinib in patients with Waldenström macroglobulinemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septiembre 2022
SIE (Sociedad Italiana de Hematología)
SIE (Sociedad Italiana de Hematología)
Septiembre 2022 (Roma, Italia)
Presentaciones
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma: subgroup analysis of the MAGNOLIA study
Zanubrutinib plus obtinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial
Pósteres
A phase 2 study with the novel B-cell lymphoma (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Resúmenes
A phase 2 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients (pts) with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib (zanu) in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Septiembre 2022
NZSO (Sociedad de Oncología de Nueva Zelanda)
NZSO (Sociedad de Oncología de Nueva Zelanda)
Septiembre 2022 (Christchurch, Nueva Zelanda)
Septiembre 2022
HSANZ (Sociedad de Hematología de Australia y Nueva Zelanda)
HSANZ (Sociedad de Hematología de Australia y Nueva Zelanda)
Septiembre 2022 (Sídney, Australia)
Presentaciones
A phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with AML
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL
Pósteres
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
Population-wide patterns of care in CLL in Australia: an analysis of the pharmaceutical benefits scheme data set
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme data set
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Population-wide patterns of care in chronic lymphocytic leukemia (CLL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset
Population-wide patterns of care in mantle cell lymphoma (MCL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septiembre 2022
ESMO (Sociedad Europea de Oncología Médica)
ESMO (Sociedad Europea de Oncología Médica)
Septiembre 2022 (París, Francia)
Pósteres
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab + tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvanTIG-205: phase 2 trial of ociperlimab plus tislelizumab plus chemotherapy in first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer
DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
SAFFRON-301: a phase 3 study of tislelizumab with sitravatinib versus chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer previously treated with platinum-based chemotherapy and an anti-PD-1/PD-L1 antibody
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with advanced non-small cell lung cancer (NSCLC): Asian and non-Asian subgroup analysis of the RATIONALE-303 study
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
AdvanTIG-205: phase 2 trial of ociperlimab (OCI) + tislelizumab (TIS) + chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)
Final analysis of RATIONALE-301: randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Phase 3 study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody
Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study
Septiembre 2022
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
Septiembre 2022 (Bydgoszcz, Polonia)
Presentaciones
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL
Resúmenes
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septiembre 2022
KSMO (Sociedad Coreana de Oncología Médica)
KSMO (Sociedad Coreana de Oncología Médica)
Septiembre 2022 (Seúl, Corea del Sur)
Presentaciones
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
HERIZON-GEA-01: phase 3 study of zanidatamab (ZANI) + chemotherapy (chemo) ± tislelizumab (TIS) in first-line (1L) human epidermal growth factor receptor 2 positive (HER2+) locally advanced (LA)/metastatic gastroesophageal adenocarcinoma (GEA)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Agosto 2022
WCLC (World Congress on Lung Cancer)
WCLC (World Congress on Lung Cancer)
Agosto 2022 (Viena, Austria)
Pósteres
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer (NSCLC): final analysis of RATIONALE-303
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, non-squamous NSCLC
Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Julio 2022
PPLC (Pan Pacific Lymphoma Conference)
PPLC (Pan Pacific Lymphoma Conference)
Julio 2022 (Kauai, Hawái)
Pósteres
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in 13 acalabrutinib‑intolerant patients with B‑Cell malignancies
Resúmenes
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib (ZANU) versus bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib in 13 acalabrutinib‑intolerant patients (pts) with B‑cell malignancies
Junio 2022
WCGI (World Congress on Gastrointestinal Cancer)
WCGI (World Congress on Gastrointestinal Cancer)
Junio 2022 (Barcelona, España)
Pósteres
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma: RATIONALE-208 Chinese subpopulation
Resúmenes
RATIONALE-306: randomized, multi-regional, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation
Junio 2022
AOS (Sociedad Asiática de Oncología)
AOS (Sociedad Asiática de Oncología)
Junio 2022 (Seúl, Corea)
Junio 2022
EHA (Asociación Europea de Hematología)
EHA (Asociación Europea de Hematología)
Junio 2022 (Viena, Austria)
Pósteres
A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress)
A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set
Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study
Resúmenes
A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress)
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Zanubrutinib in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Junio 2022
ASCO (Sociedad Estadounidense de Oncología Clínica)
ASCO (Sociedad Estadounidense de Oncología Clínica)
June 2022 (Chicago, Illinois, USA)
Presentaciones
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
RATIONALE-309: updated PFS, PFS2, and OS from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer
Pósteres
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma
Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: preliminary results from a phase 1b/2 study
Zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial
Resúmenes
A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM)
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC)
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208
Efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC), RATIONALE 302: Asia subgroup
Real world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL)
Real-world (RW) treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients (pts) with mantle cell lymphoma (MCL)
Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Mayo 2022
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
Mayo 2022 (Washington, DC, Estados Unidos)
Mayo 2022
ICCEH (International Conference on Clinical and Experimental Hematology)
ICCEH (International Conference on Clinical and Experimental Hematology)
Mayo 2022 (Lublin, Polonia)
Abril 2022
TCT (Transplantation & Cellular Therapy)
TCT (Transplantation & Cellular Therapy)
April 2022 (Salt Lake City, Utah, USA)
Abril 2022
Programa de la serie plenaria de ASCO (Sociedad Estadounidense de Oncología Clínica)
Programa de la serie plenaria de ASCO (Sociedad Estadounidense de Oncología Clínica)
Abril 2022 (virtual)
Abril 2022
AACR (Asociación Estadounidense de Investigación en Cáncer)
AACR (Asociación Estadounidense de Investigación en Cáncer)
April 2022 (New Orleans, Louisiana, USA)
Pósteres
BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
Co-enrichment of CD8 T-cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells
Prediction of intratumoral TIGIT receptor occupancy after treatment with anti-TIGIT antibodies
RATIONALE 304: tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for non-squamous NSCLC in patients aged 65-75 years
RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer
The combination of hyperamplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab
Tislelizumab versus docetaxel in patients with previously treated advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in patients with previously treated advanced squamous (sq) non-small cell lung cancer (NSCLC): subanalysis from phase 3 RATIONALE-303 randomized clinical study
Resúmenes
BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
CD8 T cells and macrophage abundances associated with clinical benefit of tislelizumab in various tumor types
Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells
Prediction of intratumoral TIGIT receptor occupancy after the treatment with anti-TIGIT antibodies
RATIONALE 304: tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65–75 years
RATIONALE-304: the association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab
Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced non-squamous (non-sq) non-small-cell lung cancer (NSCLC): subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): sub-analysis from phase 3 RATIONALE-303 randomized clinical study
Abril 2022
BSH (Sociedad Británica de Hematología)
BSH (Sociedad Británica de Hematología)
Abril 2022 (Manchester, Reino Unido)
Pósteres
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
Resúmenes
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Marzo 2022
SIES (Sociedad Italiana de Hematología Experimental)
SIES (Sociedad Italiana de Hematología Experimental)
Marzo 2022 (Roma, Italia)
Marzo 2022
KSH (Sociedad Coreana de Hematología)
KSH (Sociedad Coreana de Hematología)
Marzo 2022 (Seúl, Corea del Sur)
Marzo 2022
ELCC (Congreso Europeo de Cáncer de Pulmón)
ELCC (Congreso Europeo de Cáncer de Pulmón)
Marzo 2022 (virtual)
Pósteres
AdvanTIG-204: anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab plus concurrent chemoradiotherapy in patients with untreated limited-stage small cell lung cancer
RATIONALE-307: safety analysis of patients receiving tislelizumab plus chemotherapy versus chemotherapy alone in advanced squamous NSCLC
Resúmenes
AdvanTIG-204: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
RATIONALE-307: safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC
Marzo 2022
SFH (Sociedad Francesa de Hematología)
SFH (Sociedad Francesa de Hematología)
Marzo 2022 (París, Francia)
Marzo 2022
SGO (Sociedad de Oncología Ginecológica)
SGO (Sociedad de Oncología Ginecológica)
Marzo 2022 (Phoenix, Arizona, Estados Unidos)
Pósteres
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
Phase 2 study of tislelizumab monotherapy in previously-treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: gynecological cancer subgroup
Resúmenes
AdvanTIG-202: a phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: gynecological cancer subgroup
Marzo 2022
JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)
JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)
Marzo 2022 (París, Francia)
Marzo 2022
ESMO TAT (Terapias oncológicas dirigidas de la Sociedad Europea de Oncología Médica)
ESMO TAT (Terapias oncológicas dirigidas de la Sociedad Europea de Oncología Médica)
Marzo 2022 (virtual)
Pósteres
Febrero 2022
JSMO (Sociedad Japonesa de Oncología Médica)
JSMO (Sociedad Japonesa de Oncología Médica)
Febrero 2022 (Kioto, Japón)
Enero 2022
BTOG (Grupo Británico de Oncología Torácica)
BTOG (Grupo Británico de Oncología Torácica)
Enero 2022 (virtual)
Enero 2022
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
January 2022 (San Francisco, California, USA)
Pósteres
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma
Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208
Clinical outcomes in patients with previously treated advanced hepatocellular carcinoma experiencing hepatitis B virus DNA increases during tislelizumab treatment in RATIONALE-208
DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life
Updated analysis from a phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors
Resúmenes
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 vs TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC)
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208
DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Diciembre 2021
ASH (Sociedad Estadounidense de Hematología)
ASH (Sociedad Estadounidense de Hematología)
Diciembre 2021 (Atlanta, Georgia, Estados Unidos)
Presentaciones
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in combination with venetoclax for patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
Pósteres
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK-inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
Resúmenes
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
Diciembre 2021
ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)
ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)
Diciembre 2021 (Ginebra, Suiza)
Pósteres
AdvanTIG-301: anti-TIGIT monoclonal antibody ociperlimab + tislelizumab + concurrent chemoradiotherapy followed by ociperlimab + tislelizumab or tislelizumab + concurrent chemoradiotherapy followed by tislelizumab versus concurrent chemoradiotherapy followed by durvalumab in previously untreated, locally advanced, unresectable non-small cell lung cancer
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer
Resúmenes
AdvanTIG-301: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC
RATIONALE 309: a randomized, global, double-blind, phase 3 trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as 1L treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Diciembre 2021
IBC (Immunotherapy Bridge)
IBC (Immunotherapy Bridge)
Diciembre 2021 (virtual)
Noviembre 2021
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)
Noviembre 2021 (virtual)
Pósteres
Noviembre 2021
AMC (Conferencia Australiana sobre Melanoma)
AMC (Conferencia Australiana sobre Melanoma)
Noviembre 2021 (Sídney, Australia)
Noviembre 2021
COSA (Sociedad Australiana de Oncología Clínica)
COSA (Sociedad Australiana de Oncología Clínica)
Noviembre 2021 (Melbourne, Australia)
Noviembre 2021
SPH (Sociedad Portuguesa de Hematología)
SPH (Sociedad Portuguesa de Hematología)
Noviembre 2021 (Espinho, Portugal)
Presentaciones
Noviembre 2021
SITC (Sociedad de Inmunoterapia contra el Cáncer)
SITC (Sociedad de Inmunoterapia contra el Cáncer)
November 2021 (Washington, DC, USA)
Pósteres
Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma
Association of tumor mutation burden and genomic alterations with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab
Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma
Resúmenes
Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma
Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab
Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Octubre 2021
SIE (Sociedad Italiana de Hematología)
SIE (Sociedad Italiana de Hematología)
Octubre 2021 (Milán, Italia)
Presentaciones
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM)
Resúmenes
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenstrӧm macroglobulinemia (WM)
Octubre 2021
AMCP Nexus (Academy of Managed Care Pharmacy Nexus)
AMCP Nexus (Academy of Managed Care Pharmacy Nexus)
Octubre 2021 (Denver, Colorado, Estados Unidos)
Pósteres
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia in the United States
Real-world treatment pattern, adherence, cost and healthcare resource utilization of commercially-insured patients with Waldenstrӧm macroglobulinemia in the United States
Zanubrutinib versus ibrutinib to treat adult patients with Waldenstrӧm macroglobulinemia: a cost per response model from a payer perspective in the United States
Resúmenes
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia in the United States
Real-world treatment pattern, adherence, cost and healthcare resource utilization of commercially-insured patients with Waldenstrӧm macroglobulinemia in the United States
Zanubrutinib versus ibrutinib to treat adult patients with Waldenstrӧm macroglobulinemia: a cost per response model from a payer perspective in the United States
Octubre 2021
SEOM (Sociedad Española de Oncología Médica)
SEOM (Sociedad Española de Oncología Médica)
Octubre 2021 (virtual)
Octubre 2021
SEHH (Sociedad Española de Hematología y Hemoterapia)
SEHH (Sociedad Española de Hematología y Hemoterapia)
Octubre 2021 (Pamplona, España)
Pósteres
Octubre 2021
AGITG (Grupo de Ensayos Gastrointestinales de Australasia)
AGITG (Grupo de Ensayos Gastrointestinales de Australasia)
Octubre 2021 (virtual)
Pósteres
ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
Resúmenes
AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma
Octubre 2021
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)
Octubre 2021 (Berlín, Alemania)
Presentaciones
Septiembre 2021
SOHO (Sociedad de Oncología Hematológica)
SOHO (Sociedad de Oncología Hematológica)
Septiembre 2021 (Roma, Italia)
Presentaciones
Pósteres
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrӧm macroglobulinemia
Resúmenes
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with wild-type MYD88 Waldenstrӧm macroglobulinemia
Septiembre 2021
HSANZ (Sociedad de Hematología de Australia y Nueva Zelanda)
HSANZ (Sociedad de Hematología de Australia y Nueva Zelanda)
Septiembre 2021 (virtual)
Septiembre 2021
ESMO (Sociedad Europea de Oncología Médica)
ESMO (Sociedad Europea de Oncología Médica)
Septiembre 2021 (virtual)
Pósteres
Association between use of antibiotics and clinical outcomes with tislelizumab monotherapy
DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Effects of tislelizumab monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma
RATIONALE 304: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for non-squamous non-small cell lung cancer in patients who are smokers vs non-smokers
RATIONALE 307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer in patients who were smokers versus non-smokers
Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer
Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer
Resúmenes
Association between use of antibiotics (ATB) and clinical outcomes with tislelizumab (tisle) monotherapy
DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC)
RATIONALE 304: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first‑line (1L) treatment for non-squamous (non-sq) non-small cell lung cancer (NSCLC) in patients (pts) who are smokers vs non-smokers
RATIONALE 307: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers
Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
Septiembre 2021
iwCLL (Taller Internacional sobre LLC)
iwCLL (Taller Internacional sobre LLC)
Septiembre 2021 (virtual)
Pósteres
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukemia (CLL) in the United States
Zanubrutinib in patients with B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Resúmenes
A real-world study to assess the association of cardiovascular adverse events with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in patients with B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Septiembre 2021
CSCO (Sociedad China de Oncología Clínica)
CSCO (Sociedad China de Oncología Clínica)
Septiembre 2021 (virtual)
Presentaciones
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years
Results from RATIONALE-303: a global phase 3 study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Resúmenes
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors
A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years
Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Septiembre 2021
SFH (Sociedad Francesa de Hematología)
SFH (Sociedad Francesa de Hematología)
Septiembre 2021 (París, Francia)
Presentaciones
Pósteres
Resúmenes
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with wild-type MYD88 Waldenström macroglobulinemia (MYD88WT WM)
Septiembre 2021
WCLC (World Congress on Lung Cancer)
WCLC (World Congress on Lung Cancer)
Septiembre 2021 (virtual)
Pósteres
RATIONALE 307: a subgroup analysis of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for Stage IIIB advanced squamous NSCLC
RATIONALE-303 phase 3 tislelizumab vs docetaxel in previously treated advanced NSCLC: China subgroup analysis
RATIONALE-307: updated biomarker analysis of phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone for 1L advanced sq-NSCLC
Resúmenes
RATIONALE 307: a subgroup analysis of tislelizumab plus chemo vs chemo alone as 1L treatment for Stage IIIB advanced sq NSCLC
RATIONALE-303 phase 3 tislelizumab vs docetaxel in previously treated advanced NSCLC: China subgroup analysis
RATIONALE-307: updated biomarker analysis of phase 3 study of tislelizumab plus chemo vs chemo alone for 1L advanced sq-NSCLC
Septiembre 2021
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
Septiembre 2021 (virtual)
Agosto 2021
PPLC (Pan Pacific Lymphoma Conference)
PPLC (Pan Pacific Lymphoma Conference)
Agosto 2021 (Big Island, HI)
Julio 2021
Simposio Internacional del Instituto de Investigación Oncológica Yonsei Song-dang (N/A)
Simposio Internacional del Instituto de Investigación Oncológica Yonsei Song-dang (N/A)
Julio 2021 (Seúl, Corea del Sur)
Junio 2021
WCGI (World Congress on Gastrointestinal Cancer)
WCGI (World Congress on Gastrointestinal Cancer)
Junio 2021 (virtual)
Presentaciones
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and the Europe/North America subgroup
Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma
Resúmenes
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
Junio 2021
ICML (International Conference on Malignant Lymphoma)
ICML (International Conference on Malignant Lymphoma)
Junio 2021 (virtual)
Pósteres
Resúmenes
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Junio 2021
EHA (Asociación Europea de Hematología)
EHA (Asociación Europea de Hematología)
Junio 2021 (virtual)
Presentaciones
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Pósteres
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of a phase 2 study of zanubrutinib in patients with previously treated B cell malignancies intolerant to ibrutinib/acalabrutinib
Preliminary safety data from patients with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Resúmenes
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstrӧm macroglobulinemia: matching-adjusted indirect comparisons
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): long-term efficacy and safety results from a phase 2 study
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Junio 2021
ASCO (Sociedad Estadounidense de Oncología Clínica)
ASCO (Sociedad Estadounidense de Oncología Clínica)
Junio 2021 (virtual)
Pósteres
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-302: anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1-selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer
Efficacy and safety of zanubrutinib versus rituximab-based chemotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons
PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65
The effects of tislelizumab treatment on the health-related quality of life of non−small cell lung cancer patients who progressed on a prior platinum-containing regimen
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
Resúmenes
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-302: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) vs pembrolizumab (PEM) in programmed death ligand 1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC)
Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): matching-adjusted indirect comparisons
PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma
RATIONALE-307: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65
Real-world treatment patterns, adherence, costs and healthcare resource utilization associated with Waldenström macroglobulinemia in the United States
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen
Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical hodgkin lymphoma (cHL): long-term follow-up efficacy and safety results from a phase 2 study
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
Mayo 2021
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
Mayo 2021 (virtual)